GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivation Inc (NAS:MDVN) » Definitions » Operating Margin %

Medivation (Medivation) Operating Margin % : -303.47% (As of Jun. 2016)


View and export this data going back to 1996. Start your Free Trial

What is Medivation Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Medivation's Operating Income for the three months ended in Jun. 2016 was $-626 Mil. Medivation's Revenue for the three months ended in Jun. 2016 was $206 Mil. Therefore, Medivation's Operating Margin % for the quarter that ended in Jun. 2016 was -303.47%.

The historical rank and industry rank for Medivation's Operating Margin % or its related term are showing as below:


MDVN's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -177.195
* Ranked among companies with meaningful Operating Margin % only.

Medivation's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Medivation's Operating Income for the three months ended in Jun. 2016 was $-626 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2016 was $-257 Mil.


Medivation Operating Margin % Historical Data

The historical data trend for Medivation's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medivation Operating Margin % Chart

Medivation Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -71.09 -14.43 -8.15 39.67 43.96

Medivation Quarterly Data
Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.55 53.32 58.61 4.43 -303.47

Competitive Comparison of Medivation's Operating Margin %

For the Biotechnology subindustry, Medivation's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medivation's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medivation's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Medivation's Operating Margin % falls into.



Medivation Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Medivation's Operating Margin % for the fiscal year that ended in Dec. 2015 is calculated as

Operating Margin %=Operating Income (A: Dec. 2015 ) / Revenue (A: Dec. 2015 )
=414.613 / 943.258
=43.96 %

Medivation's Operating Margin % for the quarter that ended in Jun. 2016 is calculated as

Operating Margin %=Operating Income (Q: Jun. 2016 ) / Revenue (Q: Jun. 2016 )
=-625.641 / 206.165
=-303.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medivation  (NAS:MDVN) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Medivation Operating Margin % Related Terms

Thank you for viewing the detailed overview of Medivation's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Medivation (Medivation) Business Description

Traded in Other Exchanges
N/A
Address
Medivation Inc was formed in Delaware in October 1995. The Company is a biopharmaceutical company engaged in the rapid development of novel small molecule drugs to treat diseases for which there are limited treatment options. Together with its collaboration partner Astellas Pharma Inc., or Astellas, the Company is developing XTANDI enzalutamide capsules. Together with Astellas, it is also conducting multiple trials of enzalutamide in earlier prostate cancer disease states, including the Phase 3 PREVAIL trial in patients with mCRPC who have not received chemotherapy, or pre-chemotherapy mCRPC patients, and in patients with breast cancer. Based on the positive results of the AFFIRM trial, the Company has exercised its right under its collaboration agreement with Astellas to co-promote XTANDI in the U.S., should it receive marketing approval. Their subsidiaries are Medivation Prostate Therapeutics Inc or MPT, Medivation Neurology Inc or MNI, Medivation Technologies Inc, or MTI, Medivation Field Solutions, Inc., or MFSI, and Medivation Services, Inc., or MSI. MPT holds the intellectual property rights covering XTANDI. MNI holds the intellectual property rights covering dimebon, which was in development for Alzheimer's disease and Huntington disease under its former collaboration with Pfizer. MTI holds the intellectual property rights covering its early-stage technologies. MFSI provides commercialization services to the Company, and MSI provides research and development services. It has received "Fast Track" designation from the U.S. Food and Drug Administration for the post-docetaxel indication. The Company is conducting this program in collaboration with Astellas. The Company is subject to extensive regulation by the Federal Food, Drug, and Cosmetic Act, or the FDC Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.
Executives
W Anthony Vernon director C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, NEW YORK NY 10018
Marion Mccourt officer: Chief Operating Officer C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Tseli Lily Yang officer: VP, Finance and Accounting C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Mohammad Hirmand officer: Interim Chief Medical Officer C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
David Hung director, officer: President and CEO C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Dawn Svoronos director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Wendy L Yarno director
Jennifer Jarrett officer: Chief Financial Officer C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Kim D Blickenstaff director C/O MEDIVATION, INC., 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94105
Powell Andrew Kenneth William officer: SVP, General Counsel & Crp Sec C/O COLLAGENEX PHARMACEUTICALS, INC., 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
Patrick Machado director 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
Kathryn E Falberg director C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Rick Bierly officer: CFO (former) C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Joseph M Lobacki officer: Chief Commercial Officer C/O MICROMET, INC., 9201 CORPORATE BLVD., SUITE 400, ROCKVILLE MD 20850
Jennifer J Rhodes officer: GC & Corporate Secretary C/O ADAMAS PHARMACEUTICALS INC., 1900 POWELL ST., SUITE 750, EMERYVILLE CA 94608

Medivation (Medivation) Headlines

From GuruFocus

Steven Cohen Trims Nike, Coach, Alphabet

By Tiziano Frateschi Tiziano Frateschi 05-20-2016

Andreas Halvorsen Buys 2 Million Shares of Medivation

By Holly LaFon Holly LaFon 08-22-2012

Medivation Inc. (MDVN) President and CEO David Hung sells 25,000 Shares

By GuruFocus Research GuruFocus Editor 12-09-2009

Medivation Inc. (MDVN) President and CEO David Hung sells 25,000 Shares

By GuruFocus Research GuruFocus Editor 09-11-2009